Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Gene

WNT

2 articles · Resources: NCBI Gene, OncoKB

Clinical · Bioinfo & AI

Integrated clinicogenomic analysis reveals the evolution and metastatic tropisms of advanced colorectal cancer

Manca P, Walch H, Xu J, et al.

Cancer cell

This study performed an integrated clinicogenomic analysis on over 7,000 colorectal cancer (CRC) samples to characterize its genetic drivers and metastatic tropisms. Researchers found that genomic evolutionary changes, such as clonal mutations and oncogenic mutant allelic imbalance, enhance the impact of recurrent oncogenic alterations. The study identified the relative timing of organ-specific metastasis, showing sequential progression in microsatellite stable CRC, with brain and adrenal metastases as late events. It also revealed clustering of metastatic sites and genomic events that modify metastasis risk, with WNT pathway activation being protective and RAS pathway activation increasing the risk of widespread metastasis. These data suggest that integrating information about primary tumor location and genomics can predict organ-specific metastasis risk.

Clinical · Molecular biology · Bioinfo & AI

Multi-omics driven immune classification of colorectal cancer: Implications for immunotherapy efficacy prediction and enhancement with WNT signaling inhibition

Hu C, Cai D, You W, et al.

Cancer letters

This study developed a novel immune classification for colorectal cancer (CRC) through integrative multi-omics analysis. By utilizing gene expression, mutation, and methylation profiles from two large CRC cohorts, three distinct clusters (MotifCC) were identified, each with unique molecular and immune characteristics. Cluster1, featuring high WNT pathway activation, exhibited the worst prognosis and a tumor-promoting microenvironment, suggesting benefit from a combination of immunotherapy and WNT-targeted treatment. Cluster2, with low immune infiltration and high glycolysis intensity, might respond to metabolism inhibitors, while Cluster3, characterized by high gene methylation, high tumor mutation burden, and microsatellite instability, showed a better response to immunotherapy. This classification provides valuable insights for understanding CRC heterogeneity and tailoring immunotherapy strategies.